Gene · 685
Papers1,437
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
81 to 100 of 1,437
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Decoding the Intercellular Cross-Talking Between Immune Cells and Renal Innate Cells in Diabetic Kidney Disease by Bioinformatics. | J Inflamm Res | 2023 | 37497063 | PubTator, text mining | PubMed |
| CSL362 potently and specifically depletes pDCs invitro and ablates SLE-immune complex-induced IFN responses. | iScience | 2023 | 37456846 | PubTator, text mining | PubMed |
| An Overview of EGFR Mechanisms and Their Implications in Targeted Therapies for Glioblastoma. | Int J Mol Sci | 2023 | 37446288 | PubTator, text mining | PubMed |
| The Potential Role of Epigallocatechin-3-Gallate (EGCG) in Breast Cancer Treatment. | Int J Mol Sci | 2023 | 37445915 | PubTator, text mining | PubMed |
| inMTSCCA: An Integrated Multi-task Sparse Canonical Correlation Analysis for Multi-omic Brain Imaging Genetics. | Genomics Proteomics Bioinformatics | 2023 | 37442417 | PubTator, text mining | PubMed |
| Machine learning-based screening for biomarkers of psoriasis and immune cell infiltration. | Eur J Dermatol | 2023 | 37431117 | PubTator, text mining | PubMed |
| The Mediator complex regulates enhancer-promoter interactions. | Nat Struct Mol Biol | 2023 | 37430065 | PubTator, text mining | PubMed |
| Biomarker analysis of the phase II JO25567 study comparing erlotinib with or without bevacizumab in first-line advanced EGFR+non-small-cell lung cancer. | Transl Lung Cancer Res | 2023 | 37425411 | PubTator, text mining | PubMed |
| Effects of Dehydroepiandrosterone (DHEA) Supplementation on Ovarian Cumulus Cells following In Vitro Fertilization (IVF)/Intra-Cytoplasmic Sperm Injection (ICSI) Treatment-A Systematic Review. | Life (Basel) | 2023 | 37374020 | PubTator, text mining | PubMed |
| Mass Spectrometry and Pharmacological Approaches to Measuring Cooption and Reciprocal Activation of Receptor Tyrosine Kinases. | Proteomes | 2023 | 37368466 | PubTator, text mining | PubMed |
| P110α inhibitor alpelisib exhibits a synergistic effect with pyrotinib and reverses pyrotinib resistant in HER2+ breast cancer. | Neoplasia | 2023 | 37348428 | PubTator, text mining | PubMed |
| Trapping all ERBB ligands decreases pancreatic lesions in a murine model of pancreatic ductal adenocarcinoma. | Mol Oncol | 2023 | 37341059 | PubTator, text mining | PubMed |
| Targeting Epidermal Growth Factor Receptor for Cancer Treatment: Abolishing Both Kinase-Dependent and Kinase-Independent Functions of the Receptor. | Pharmacol Rev | 2023 | 37339882 | PubTator, text mining | PubMed |
| The Endogenous Dual Retinoid Receptor Agonist Alitretinoin Exhibits Immunoregulatory Functions on Antigen-Presenting Cells. | Int J Mol Sci | 2023 | 37298605 | PubTator, text mining | PubMed |
| Pancreatic β-cell heterogeneity in adult human islets and stem cell-derived islets. | Cell Mol Life Sci | 2023 | 37270452 | PubTator, text mining | PubMed |
| Targeting the EGFR signaling pathway in cancer therapy: What's new in 2023? | Expert Opin Ther Targets | 2023 | 37243489 | PubTator, text mining | PubMed |
| Betacellulin regulates gap junction intercellular communication by inducing the phosphorylation of connexin 43 in human granulosa-lutein cells. | J Ovarian Res | 2023 | 37231448 | PubTator, text mining | PubMed |
| Bioinformatic Analysis of the Potential Common Pathogenic Mechanisms for Psoriasis and Metabolic Syndrome. | Inflammation | 2023 | 37222907 | PubTator, text mining | PubMed |
| ERBB Receptors and Their Ligands in the Developing Mammary Glands of Different Species: Fifteen Characters in Search of an Author. | J Mammary Gland Biol Neoplasia | 2023 | 37219601 | PubTator, text mining | PubMed |
| Biased activation of the receptor tyrosine kinase HER2. | Cell Mol Life Sci | 2023 | 37208479 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/685/papers?page=5